We are delighted to be a co-organiser of the Pathways to Access Summit in The Netherlands in June. Our founder Tadeusz is also speaking at the event.

With the FDA likely approving MDMA-assisted therapy as a treatment for PTSD later this year in the United States, and the evidence supporting the potential of psychedelic therapies further accumulating, 2024 is shaping up to be a pivotal year for the therapeutic use of psychedelics. However, the path to approval and - crucially - patient access in Europe remains uncertain. 
The full-day Pathways to Access Summit (Paths) convenes key stakeholders from Europe and beyond to explore the opportunities and challenges around the development, approval, and eventual integration of psychedelic medicines into mainstream European health care.

This summit will unravel the complexities of European regulatory frameworks, addressing the diverse and ever-changing healthcare systems, assessments for pricing and reimbursement, and unique regulatory challenges. We will identify which stakeholders to engage with at each stage of the journey from bench to bedside and share best practices for doing so. We will discuss how to effectively navigate the European regulatory landscape, incorporating insights from other regulatory systems, and offer a well-rounded perspective on the different approaches and best practices to psychedelic medicine regulation.

Are you a researcher, drug developer, policymaker, regulator, student, or therapist eager to influence the future of psychedelic therapies in Europe?

Join us at the Pathways to Access Summit and take an active role in shaping the dialogue.

As a special incentive, use our exclusive co-organiser discount code: PAREA100, to receive €100 off (33% discount) your ticket. Secure your place here.

Discover more about the summit and view the full programme here.